Plod2 Antibody

What is PLOD2 and what is its functional significance in research?

PLOD2, with a calculated molecular weight of 85 kDa (observed at 87 kDa), is an enzyme involved in collagen modification that has emerged as a significant factor in tumor progression. This protein is encoded by the PLOD2 gene (GenBank accession number BC037169, Gene ID 5352) . Recent studies have demonstrated its crucial role in promoting cancer cell migration, invasion, and angiogenesis in multiple tumor types, making it a valuable target for cancer research .

What are the validated applications for PLOD2 antibodies?

PLOD2 antibodies have been successfully employed across multiple experimental platforms. According to extensive validation studies, they can be reliably used for Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence/Immunocytochemistry (IF/ICC), Flow Cytometry (FC), Immunoprecipitation (IP), and ELISA applications . The antibody shows consistent reactivity with human, mouse, and rat samples, with cited reactivity extending to rabbit and zebrafish models as well .

What experimental systems have been validated for PLOD2 detection?

The following table summarizes validated experimental systems for PLOD2 antibody applications:

Source: Proteintech PLOD2 Antibody validation data

What dilutions are recommended for PLOD2 antibody applications?

Optimal antibody dilutions are critical for generating reliable and reproducible results. Based on extensive validation studies, the following dilutions are recommended for different applications:

Note: It is recommended that researchers titrate the antibody in their specific testing system to obtain optimal results, as optimal dilutions may be sample-dependent .

What antigen retrieval methods are most effective for PLOD2 immunohistochemistry?

For optimal immunohistochemical detection of PLOD2, TE buffer at pH 9.0 is the suggested primary antigen retrieval method . Alternatively, citrate buffer at pH 6.0 can be used effectively. Recent research protocols have specifically employed sodium citrate buffer (pH 6.0) for 20 minutes at 95°C for successful antigen retrieval when studying PLOD2 in osteosarcoma tissues . These parameters should be optimized for specific tissue types and fixation conditions.

How should PLOD2 knockdown experiments be designed and validated?

For functional studies investigating PLOD2's role in biological processes, both transient and stable knockdown approaches have proven effective. In transient knockdown experiments, researchers have successfully used small interfering RNAs (siRNAs) transfected into cell lines using Lipofectamine 2000, with knockdown efficiency assessed 48 hours post-transfection via RT-qPCR . For stable knockdown, lentivirus-containing short hairpin RNA (shRNA) systems followed by puromycin selection (2μg/mL for 2 weeks) have been demonstrated to effectively generate stable PLOD2-deficient cell lines . Validation of knockdown efficiency is essential before proceeding with functional assays.

How does PLOD2 contribute to tumor progression mechanisms?

Multiple studies have established PLOD2 as a crucial factor in cancer progression. In osteosarcoma, PLOD2 has been demonstrated to promote migration, invasion, and angiogenesis in vitro and facilitate metastasis and angiogenesis in vivo . Similarly, in hepatocellular carcinoma (HCC), PLOD2 dysregulation has been shown to promote tumor metastasis and invasion . The enzyme's role in collagen modification likely affects extracellular matrix remodeling, which is a critical component of the metastatic cascade, though specific molecular mechanisms require further investigation in each cancer type.

How does PLOD2 expression correlate with immune cell infiltration in tumors?

Bioinformatic analysis has revealed that PLOD2 expression negatively correlates with immune infiltration in several cancer types. In osteosarcoma specifically, PLOD2 expression showed significant negative correlation with the infiltration of CD4 and CD8A T cells . Immunohistochemical analysis confirmed that CD4 and CD8A were lowly expressed in PLOD2-high expressing OS tissues, while being highly expressed in PLOD2-low expressing OS tissues . This suggests PLOD2 may function as an immune suppressor in tumor progression, potentially helping cancer cells evade immune surveillance.

What analytical approaches are recommended for investigating PLOD2's relationship with immune infiltration?

Researchers have employed several sophisticated analytical approaches to characterize the relationship between PLOD2 and immune infiltration:

• TIMER software for systematic evaluation of immune cell infiltration and its clinical impact

• CIBERSORT R package for analyzing profiles of 22 tumor-infiltrating immune cells

• xCell R package for broader immune cell infiltration analysis

• Correlation analysis between PLOD2 expression and specific immune cell markers

• Immunohistochemical validation of computational findings in tissue samples

These complementary approaches provide robust characterization of PLOD2's immunomodulatory functions in the tumor microenvironment.

How can researchers identify PLOD2 as a gene of interest in cancer studies?

Researchers have employed a multi-omics approach to identify PLOD2 as a key gene in cancer progression. This includes:

• RNA-seq of tumor and adjacent normal tissues to identify differentially expressed genes

• Filtering for significantly up-regulated genes (logFC>1.5, P.adj<0.05)

• Validation across multiple independent datasets (e.g., GEO database)

• Taking the intersection of multiple RNA-seq results to identify consistently altered genes

• Functional validation through knockdown experiments

This systematic approach helps establish PLOD2 as a robust candidate for further investigation.

What statistical methods are appropriate for analyzing PLOD2 expression data?

Statistical rigor is essential for PLOD2 research. Recommended statistical approaches include:

How should researchers interpret discrepancies between PLOD2 protein and mRNA levels?

While the search results don't directly address this issue, researchers should consider several factors when facing such discrepancies:

• Post-transcriptional regulation mechanisms affecting translation efficiency

• Protein stability and degradation rates differing from mRNA turnover

• Technical variations in detection methodologies (antibody specificity for protein detection vs. primer efficiency for mRNA quantification)

• Temporal dynamics, as protein expression may lag behind mRNA expression changes

Multi-modal validation using complementary techniques (RT-qPCR, Western blot, IHC) is recommended to comprehensively characterize PLOD2 expression.

What bioinformatic tools are recommended for PLOD2 functional analysis?

Several bioinformatic tools have proven valuable for PLOD2 research:

• 'limma' package for differential expression analysis

• ClusterProfiler package for KEGG pathway and GO function enrichment analysis

• 'ggplot2' package for data visualization through boxplots

• 'pheatmap' package for creating expression heatmaps

• Immune Subtype Classifier and xgboost R package for immune subtype analysis

These tools facilitate comprehensive characterization of PLOD2's functional impact and biological significance.

How should researchers design experiments to investigate PLOD2's role in immune evasion?

Building on recent findings of PLOD2's potential role in immune evasion, researchers should consider:

• Co-culture experiments with cancer cells and immune cells under PLOD2 modulation

• Analysis of cytokine/chemokine profiles in PLOD2-high versus PLOD2-low environments

• In vivo studies with immune-competent models comparing tumor growth and immune infiltration with PLOD2 manipulation

• Investigation of signaling pathways connecting PLOD2 activity to immunomodulatory effects

• Correlation studies between PLOD2 expression and response to immunotherapies

These approaches would help elucidate the detailed molecular mechanisms underlying how PLOD2 regulates immune infiltration .

What unresolved questions remain regarding PLOD2 function in cancer?

Despite significant progress, several key questions remain:

• The precise molecular mechanisms by which PLOD2 regulates immune cell infiltration

• The potential of PLOD2 as a biomarker for immunotherapy response

• The tissue-specific roles of PLOD2 across different cancer types

• The therapeutic potential of targeting PLOD2 in combination with immunotherapies

• The relationship between PLOD2-mediated collagen modification and changes in the tumor microenvironment

Further research addressing these questions could significantly advance our understanding of PLOD2's role in cancer and potentially identify new therapeutic approaches .